BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
Eric L. Smith(Dana-Farber Cancer Institute), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center), Jonathan Landa(United States Fish and Wildlife Service), Isabelle Rivière(Memorial Sloan Kettering Cancer Center), Mark B. Geyer(Memorial Sloan Kettering Cancer Center), Anthony F. Daniyan(Memorial Sloan Kettering Cancer Center), Andreas Rimner(University Medical Center Freiburg), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Brigitte Sénéchal(Memorial Sloan Kettering Cancer Center), Mette Stæhr(Memorial Sloan Kettering Cancer Center), Ola Landgren(University of Miami Health System), Xiuyan Wang(Memorial Sloan Kettering Cancer Center), Bianca Santomasso(Georgetown University), Elena Mead, Terence J. Purdon(Memorial Sloan Kettering Cancer Center)
Cited by 94
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
|Nature Reviews Clinical Oncology|2019|1.4k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560